Alnylam Pharmaceuticals (NASDAQ: ALNY), widely recognized as a pioneer in RNA interference (RNAi) therapeutics, has announced plans to initiate a large-scale Phase 3 cardiovascular outcomes trial for its experimental therapy zilebesiran. The decision, revealed alongside new data presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, comes on the back of encouraging results from the company’s Phase 2 KARDIA program, including the pivotal KARDIA-3 study.
Zilebesiran, administered subcutaneously, is designed to silence the gene responsible for producing angiotensinogen (AGT), the upstream precursor in the renin-angiotensin-aldosterone system (RAAS) pathway, which plays a central role in blood pressure regulation and cardiovascular health. Alnylam, in partnership with Roche, now aims to advance the therapy into ZENITH, a Phase 3 cardiovascular outcomes trial expected to enroll about 11,000 patients worldwide by the end of 2025.
Why is Alnylam advancing zilebesiran into a Phase 3 cardiovascular outcomes trial?
The move to initiate a global Phase 3 study is rooted in the data generated by the KARDIA Phase 2 program, particularly the KARDIA-3 trial. This trial evaluated zilebesiran in patients with uncontrolled hypertension who were already on at least two antihypertensive medications, including a diuretic, and were considered at high cardiovascular risk.
According to the results presented at ESC 2025, a single 300 mg dose of zilebesiran produced a clinically meaningful reduction of systolic blood pressure (SBP) by an average of 5 mmHg at the three-month primary endpoint, with sustained reductions of nearly 4 mmHg at six months. Notably, patients with a baseline SBP of 140 mmHg or higher, who were also taking a diuretic, experienced more pronounced benefits, with reductions of over 8 mmHg at three months that were sustained through six months.
The data also revealed that increasing the dose to 600 mg did not provide additional benefit compared to the 300 mg dose, which may streamline dosing strategies as the therapy moves into Phase 3.
From a clinical perspective, a 5 mmHg drop in systolic blood pressure has been historically linked to a significant reduction in major cardiovascular events such as stroke, myocardial infarction, and heart failure. Cardiologists at the Duke Clinical Research Institute noted that zilebesiran’s ability to provide continuous blood pressure control, including during nighttime hours when elevated blood pressure is a strong predictor of adverse outcomes, marks a potentially transformative step in hypertension management.
How does zilebesiran differ from traditional hypertension treatments?
Unlike standard antihypertensive drugs such as ACE inhibitors, angiotensin receptor blockers (ARBs), or calcium channel blockers, zilebesiran employs RNAi technology to directly target AGT in the liver. By silencing this precursor protein, the drug disrupts the upstream activity of the RAAS pathway, which is central to regulating blood pressure and fluid balance.
The most common challenge in hypertension management is patient adherence. Many individuals require two or more medications, and the complexity of daily pill regimens can lead to poor compliance. Zilebesiran addresses this issue with its biannual dosing regimen—just two injections per year—providing long-term blood pressure control without the need for daily adherence.
Safety data from KARDIA-3 was also favorable. Over 90% of patients in the study were already on ACE inhibitors or ARBs, yet zilebesiran was well tolerated in combination with these therapies. Reported adverse events were largely mild or moderate, with low incidences of hyperkalemia, kidney dysfunction, or hypotension. Importantly, no deaths were reported during the six-month double-blind treatment period.
What does the KARDIA-3 trial reveal about efficacy and biomarker improvement?
KARDIA-3, which enrolled 270 patients in Cohort A with estimated glomerular filtration rates (eGFR) of at least 45 mL/min/1.73 m², stratified participants by baseline blood pressure, diuretic use, and race. Roughly 53% of patients were on two antihypertensive medications, 36% on three, and 11% on more than three.
The trial’s primary endpoint—change in office SBP at three months—was achieved in patients receiving the 300 mg dose, who recorded an average reduction of 5.0 mmHg versus placebo. The effect persisted at six months with a 3.9 mmHg reduction, though statistical testing did not meet the strict prespecified multiplicity criteria. Nevertheless, subgroup analyses indicated particularly strong benefits for patients with higher baseline blood pressure and those on diuretic therapy, with reductions surpassing 8 mmHg across 24-hour ambulatory monitoring.
Beyond blood pressure control, zilebesiran also demonstrated positive effects on prognostic biomarkers such as NT-proBNP and urinary albumin-to-creatinine ratio (UACR). These markers are critical indicators of cardiac stress and kidney health, suggesting that zilebesiran’s therapeutic potential may extend beyond hypertension management into broader cardiovascular and renal protection.
How does Alnylam’s RNAi platform position it in the cardiovascular and biotech market?
Alnylam has long been recognized as a leader in RNA interference, pioneering a therapeutic modality that targets genetic drivers of disease by silencing the production of specific proteins. The company already has four FDA-approved RNAi therapies, primarily in rare diseases such as hereditary transthyretin amyloidosis and acute hepatic porphyria.
The push into cardiovascular disease represents a significant expansion strategy. Hypertension affects more than 1.2 billion people globally, with nearly half of adults in the United States alone diagnosed with high blood pressure. Despite a wide range of available antihypertensives, nearly 70% of patients fail to achieve adequate control, underscoring the unmet medical need.
By leveraging its RNAi platform to target AGT upstream in the RAAS cascade, Alnylam is attempting to establish a differentiated, long-acting therapy that could complement or even replace traditional small-molecule drugs. Industry analysts have suggested that if zilebesiran succeeds in Phase 3 and gains regulatory approval, it could become a multibillion-dollar product, positioning Alnylam and its partner Roche to challenge incumbents in the cardiovascular drug market such as Novartis, AstraZeneca, and Johnson & Johnson.
What are the next steps for Alnylam and Roche with the ZENITH Phase 3 study?
The forthcoming ZENITH trial is designed as a cardiovascular outcomes trial, enrolling about 11,000 patients across more than 30 countries. Participants will include individuals with uncontrolled hypertension who are either living with established cardiovascular disease or at high risk of developing it, despite already receiving at least two antihypertensive medications, including a diuretic.
The trial will test zilebesiran at a 300 mg dose administered every six months, compared with placebo. The primary goal is to determine whether the therapy can significantly reduce the risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure-related hospitalization.
Alnylam and Roche expect to begin enrollment by the end of 2025, with the trial likely running for several years given the large patient population and cardiovascular outcomes focus. Results from KARDIA-3 Cohort B, which enrolled patients with more advanced kidney dysfunction (eGFR 30–45 mL/min/1.73 m²), are anticipated at an upcoming medical conference and may further inform Phase 3 trial design.
The companies have also submitted clinical trial applications to regulators across multiple geographies, indicating confidence in zilebesiran’s profile and a commitment to rapid global development.
How have investors responded to Alnylam Pharmaceuticals’ latest hypertension trial update?
Alnylam Pharmaceuticals, trading on the NASDAQ under the ticker ALNY, has historically been viewed as one of the more innovative biotechnology companies due to its leadership in RNAi therapies. Following the announcement of the KARDIA-3 data and the planned ZENITH trial, early market sentiment has been cautiously optimistic. Analysts noted that while the Phase 2 trial did not fully meet its stringent statistical endpoints, the observed blood pressure reductions—especially in patients with higher baseline readings—were clinically meaningful and consistent with prior KARDIA-2 results.
Investor reactions appear mixed but lean positive. Some market participants highlighted that zilebesiran’s long dosing interval could be a major differentiator in a hypertension drug market valued at more than $30 billion globally. Others noted that the lack of a clear dose-response between 300 mg and 600 mg may raise questions about trial design in Phase 3.
Alnylam’s stock (NASDAQ: ALNY) has seen periods of volatility in 2025, in part due to broader biotech sector pressures and investor caution around high-cost drug development. As of late August 2025, shares have experienced modest gains following the ESC announcement, reflecting investor recognition of zilebesiran’s potential to become a significant growth driver in Alnylam’s pipeline. Institutional investors appear to be cautiously increasing positions, according to recent fund flow data, though many remain focused on Phase 3 risk and the high costs associated with cardiovascular outcomes studies.
What could zilebesiran mean for the treatment landscape in hypertension and cardiovascular disease?
The potential introduction of zilebesiran could mark a pivotal shift in how physicians manage hypertension, particularly for patients who remain uncontrolled despite taking multiple medications. With hypertension being the leading modifiable risk factor for cardiovascular disease worldwide, even modest reductions in blood pressure have an outsized impact on long-term outcomes.
A twice-yearly RNAi therapy would not only simplify treatment regimens but could also help address adherence challenges that currently limit the effectiveness of standard-of-care options. This could be especially impactful in underserved regions where medication access and continuity of care are inconsistent.
From a business perspective, Alnylam and Roche are positioning themselves to expand RNAi beyond rare diseases and into mainstream cardiometabolic care, where the patient population is exponentially larger. If successful, zilebesiran could become a cornerstone therapy for uncontrolled hypertension, potentially reshaping the competitive landscape and opening new revenue streams for both companies.
The transition from promising Phase 2 data to a massive Phase 3 cardiovascular outcomes trial reflects both the scientific ambition and financial risk inherent in late-stage drug development. Success could cement Alnylam’s status as not just a rare disease innovator but also a global leader in cardiovascular medicine. For investors, the upcoming ZENITH trial will be the critical test. Until then, sentiment is likely to remain cautiously constructive, with analysts suggesting a “hold” stance while awaiting clarity on regulatory milestones and trial progress.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
